InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,312.80
(
0.08%
)
Dow Jones
42,124.65
(
0.15%
)
Brent Oil
74.08
(
0.46%
)
Bitcoin
63,133.53
(
-0.31%
)
Post# of 6072
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

FLY HIGH NOW

Send PM Follow Ignore
Followers 10
Posts 433
Boards Moderated 0
Alias Born 04/27/2011

FLY HIGH NOW

Re: None

Friday, 03/28/2014 12:43:27 AM

Friday, March 28, 2014 12:43:27 AM

Post# of 6072
they said that we should review Section 2.4 and Section 2.5 of the Contingent Value Rights Agreement which describes the procedures for ascertaining whether a milestone has been achieved and the payment procedures. You may also review the Company’s Form 10-K for additional information regarding the Company’s products.
If we have any question,we can call or email them from the contact info on their website.
Spectrum Pharmaceuticals

InvestorRelations@sppirx.com

http://www.sppirx.com


http://www.sec.gov/Archives/edgar/data/831547/000119312513295701/d568990d8k.htm
Form 8-K

http://www.sec.gov/Archives/edgar/data/831547/000119312513295701/d568990dex23.htm
Contingent Value Rights Agreement
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up